Literature DB >> 26490317

Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.

Stéphanie Poulain1, Christophe Roumier2, Aurélie Venet-Caillault3, Martin Figeac4, Charles Herbaux5, Guillemette Marot6, Emmanuelle Doye3, Elisabeth Bertrand7, Sandrine Geffroy3, Frédéric Lepretre4, Olivier Nibourel2, Audrey Decambron8, Eileen Mary Boyle5, Aline Renneville3, Sabine Tricot8, Agnès Daudignon8, Bruno Quesnel9, Patrick Duthilleul8, Claude Preudhomme2, Xavier Leleu10.   

Abstract

PURPOSE: Whole-genome sequencing has revealed MYD88 L265P and CXCR4 mutations (CXCR4(mut)) as the most prevalent somatic mutations in Waldenström macroglobulinemia. CXCR4 mutation has proved to be of critical importance in Waldenström macroglobulinemia, in part due to its role as a mechanism of resistance to several agents. We have therefore sought to unravel the different aspects of CXCR4 mutations in Waldenström macroglobulinemia. EXPERIMENTAL
DESIGN: We have scanned the two coding exons of CXCR4 in Waldenström macroglobulinemia using deep next-generation sequencing and Sanger sequencing in 98 patients with Waldenström macroglobulinemia and correlated with SNP array landscape and mutational spectrum of eight candidate genes involved in TLR, RAS, and BCR pathway in an integrative study.
RESULTS: We found all mutations to be heterozygous, somatic, and located in the C-terminal domain of CXCR4 in 25% of the Waldenström macroglobulinemia. CXCR4 mutations led to a truncated receptor protein associated with a higher expression of CXCR4. CXCR4 mutations pertain to the same clone as to MYD88 L265P mutations but were mutually exclusive to CD79A/CD79B mutations (BCR pathway). We identified a genomic signature in CXCR4(mut) Waldenström macroglobulinemia traducing a more complex genome. CXCR4 mutations were also associated with gain of chromosome 4, gain of Xq, and deletion 6q.
CONCLUSIONS: Our study panned out new CXCR4 mutations in Waldenström macroglobulinemia and identified a specific signature associated to CXCR4(mut), characterized with complex genomic aberrations among MYD88L265P Waldenström macroglobulinemia. Our results suggest the existence of various genomic subgroups in Waldenström macroglobulinemia. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26490317     DOI: 10.1158/1078-0432.CCR-15-0646

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  37 in total

Review 1.  The role of G protein-coupled receptors in lymphoid malignancies.

Authors:  Adrienne Nugent; Richard L Proia
Journal:  Cell Signal       Date:  2017-08-09       Impact factor: 4.315

2.  Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.

Authors:  C Baer; F Dicker; W Kern; T Haferlach; C Haferlach
Journal:  Leukemia       Date:  2016-11-14       Impact factor: 11.528

3.  Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.

Authors:  Zachary R Hunter; Lian Xu; Nickolas Tsakmaklis; Maria G Demos; Amanda Kofides; Cristina Jimenez; Gloria G Chan; Jiaji Chen; Xia Liu; Manit Munshi; Joshua Gustine; Kirsten Meid; Christopher J Patterson; Guang Yang; Toni Dubeau; Mehmet K Samur; Jorge J Castillo; Kenneth C Anderson; Nikhil C Munshi; Steven P Treon
Journal:  Blood Adv       Date:  2018-11-13

Review 4.  Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond.

Authors:  Richard Rosenquist; Andreas Rosenwald; Ming-Qing Du; Gianluca Gaidano; Patricia Groenen; Andrew Wotherspoon; Paolo Ghia; Philippe Gaulard; Elias Campo; Kostas Stamatopoulos
Journal:  Haematologica       Date:  2016-09       Impact factor: 9.941

5.  Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

Authors:  Zachary R Hunter; Lian Xu; Guang Yang; Nicholas Tsakmaklis; Josephine M Vos; Xia Liu; Jie Chen; Robert J Manning; Jiaji G Chen; Philip Brodsky; Christopher J Patterson; Joshua Gustine; Toni Dubeau; Jorge J Castillo; Kenneth C Anderson; Nikhil M Munshi; Steven P Treon
Journal:  Blood       Date:  2016-06-14       Impact factor: 22.113

6.  TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation.

Authors:  Jennifer Shrimpton; Matthew A Care; Jonathan Carmichael; Kieran Walker; Paul Evans; Charlotte Evans; Ruth de Tute; Roger Owen; Reuben M Tooze; Gina M Doody
Journal:  Blood Adv       Date:  2020-06-23

7.  Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.

Authors:  Jorge J Castillo; Ramon Garcia-Sanz; Evdoxia Hatjiharissi; Robert A Kyle; Xavier Leleu; Mary McMaster; Giampaolo Merlini; Monique C Minnema; Enrica Morra; Roger G Owen; Stephanie Poulain; Marvin J Stone; Constantine Tam; Marzia Varettoni; Meletios A Dimopoulos; Steven P Treon; Efstathios Kastritis
Journal:  Br J Haematol       Date:  2016-07-05       Impact factor: 6.998

Review 8.  Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

Authors:  Steven P Treon; Lian Xu; Maria Luisa Guerrera; Cristina Jimenez; Zachary R Hunter; Xia Liu; Maria Demos; Joshua Gustine; Gloria Chan; Manit Munshi; Nicholas Tsakmaklis; Jiaji G Chen; Amanda Kofides; Romanos Sklavenitis-Pistofidis; Mark Bustoros; Andrew Keezer; Kirsten Meid; Christopher J Patterson; Antonio Sacco; Aldo Roccaro; Andrew R Branagan; Guang Yang; Irene M Ghobrial; Jorge J Castillo
Journal:  J Clin Oncol       Date:  2020-02-21       Impact factor: 44.544

9.  Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.

Authors:  Shahrzad Jalali; Tammy Price-Troska; Jonas Paludo; Jose Villasboas; Hyo-Jin Kim; Zhi-Zhang Yang; Anne J Novak; Stephen M Ansell
Journal:  Blood Adv       Date:  2018-08-14

Review 10.  What is new in the treatment of Waldenstrom macroglobulinemia?

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Leukemia       Date:  2019-10-07       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.